ArticlePeerJ2025
Impact of nonalcoholic fatty liver disease on the functional cure of nucleos(t)ide analogues-treated chronic hepatitis B patients add-on pegylated interferon therapy: a retrospective study.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to determine whether nonalcoholic fatty liver disease (NAFLD) influences the functional cure of nucleos(t)ide analogues (NAs)-treated chronic hepatitis B (CHB) patients in combination with pegylated interferon (PEG-IFN) therapy. Methods: A retrospective analysis was conducted on CHB patients treated with nucleos(t)ide analogues (NAs) who received PEG-IFN combination therapy at a single center. Patients were stratified into a CHB group and a CHB-NAFLD group based on the presence of fatty liver comorbidity. The primary endpoint was the difference in hepatitis B virus surface antigen (HBsAg) seroclearance rates between the two groups, and the secondary endpoint was the differences in biochemical parameters and adverse events. Results: A total of 158 NAs-treated CHB patients were enrolled, comprising 91 CHB -only patients and 67 CHB-NAFLD patients. After 48 weeks of PEG-IFN therapy, 20.9% of patients achieved HBsAg seroclearance. Before and after propensity score matching (PSM), differences in cumulative HBsAg seroclearance probability between groups were non-significant (25.3% Conclusion: NAFLD does not affect the achievement of functional cure with PEG-IFN therapy in NAs-treated chronic hepatitis B patients. However, CHB patients with NAFLD show a reduced likelihood of ALT normalization during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.